ClinicalTrials.gg
CompletedNCT00842270Updated Dec 11, 2018

Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma

A Phase 2 interventional study of AB1010 and AB1010 in Asthma, sponsored by AB Science. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by AB Science · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to evaluate, comparatively to a placebo, the activity of oral AB1010, administered at three dose levels during 4 months to patients with severe persistent corticosteroid dependent asthma, assessed on :

  • the decrease in corticosteroid therapy
  • the asthma control improvement (symptomatic scores, rescue medication intake, respiratory function)
  • the pharmacokinetic profile of AB1010
  • clinical and biological safety parameters
Read the detailed description

This is a double-blind, placebo-controlled, randomized, parallel-groups, multicenter study of daily oral AB1010 at doses 3, 4.5 and 6 mg/kg/day.

The study treatment is administered for 16 weeks:

  • the first 4 weeks are a run-in period during which corticosteroids remain stable;
  • during the following 8 weeks, corticosteroids are decreased every week until weaning or an exacerbation occurs;
  • the last 4 weeks are a stabilization period. Patients have to perform a visit every 2 weeks during run-in, then every week for the following 3 months.
02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • severe asthma
  • corticosteroids dependent
  • asthma exacerbation
  • weaning
  • tyrosine kinase inhibitor
  • severe persistent corticosteroid dependent asthma
03

In context

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

This study's enrollment of 44 is below the median of 79 across 3,344 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known severe persistent dependent asthma (WHO/NHLBI workshop definition).
  • Disease duration > 1 year.
  • Stable disease with no exacerbation episode for at least one month before inclusion.
  • Daily treated with 10 to 50 mg of equivalent prednisolone, with stable dosage since at least 3 months.
  • Known reversibility of bronchial obstruction, defined as an enhancement of ≥ 12%, 10 minutes after salbutamol administration, or 14 days after systemic treatment with 1 mg/kg/day of equivalent prednisolone.

Exclusion criteria

Exclusion Criteria:

  • Asthmatic patients still exposed to allergens or to triggering factors influencing asthma control.
  • History of infection requiring hospitalization or treatment with antibiotics within 2 weeks of screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    2

    4,5 mg/kg/day

    Drug: AB1010

  • Experimental
    3

    6 mg/kg/day

    Drug: AB1010

  • Placebo comparator
    4

    matching placebo for AB1010 3, 4,5 and 6 mg/kg/day

    Drug: placebo

  • Experimental
    1

    AB1010 3 mg/kg/day

    Drug: AB1010

Interventions

  • DrugAB1010

    3 mg/kg/day

    Also known as: masitinib

  • DrugAB1010

    4,5 mg/kg/day

    Also known as: masitinib

  • DrugAB1010

    6 mg/kg/day

    Also known as: masitinib

  • Drugplacebo

    matching placebo to AB1010 dosages

06

What researchers measure

Primary outcomes

  1. decrease in oral corticosteroid therapy (weaning extent)

    Time frame: 16 weeks

Secondary outcomes

  1. asthma control improvement

    Time frame: 16 weeks

  2. asthma exacerbation rate

    Time frame: 16 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lee-Fowler TM, Guntur V, Dodam J, Cohn LA, DeClue AE, Reinero CR. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int Arch Allergy Immunol. 2012;158(4):369-74. doi: 10.1159/000335122. Epub 2012 Apr 4. PubMed 22487554 ↗
  • Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009 Aug;64(8):1194-201. doi: 10.1111/j.1398-9995.2009.02122.x. PubMed 19614621 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006 and a primary completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2009
First posted
Feb 12, 2009
Start
Jan 2006
Primary completionActual
Jul 2007
Last update
Dec 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00842270
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Feb 12, 2009
Start date
Jan 2006
Primary completion
Jul 2007
Last update
Dec 11, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion